免疫治疗黑色素瘤患者早期疗效评估中体积PET参数的预后价值
回顾性纳入85例接受免疫检查点抑制剂治疗的黑色素瘤患者,在基线及免疫治疗开始约3个月后行18F-FDG PET/CT,测量全身代谢肿瘤体积(MTV)等参数。首次再分期PET/CT的MTV(MTVpost)是OS最强的预后因素,高MTVpost(≥23.44)中位OS为16个月,低MTVpost(<23.44)超过60个月。
要点
- 免疫治疗约3个月后PET/CT的MTVpost是黑色素瘤患者OS的独立预后因素。
- 高MTVpost(≥23.44)中位OS 16个月,低MTVpost(<23.44)超过60个月。
- 本队列仅1例(1.2%)假性进展,评估再分期PET时需考虑其可能。
核心结论
- 免疫治疗开始约3个月后PET扫描获得的全身代谢肿瘤体积(MTVpost)是黑色素瘤患者OS的强预后指标。
- 评估首次再分期PET影像时需考虑假性进展的可能,但本队列中仅1例患者出现。
研究设计与样本
- 回顾性纳入85例接受免疫检查点抑制剂(ICI)治疗的连续黑色素瘤患者(男57例,女28例),在免疫治疗前及开始约3个月后行PET/CT扫描。
- 测量每次扫描所有黑色素瘤病灶的MTV等代谢肿瘤参数,采用Cox比例风险模型进行单因素和多因素分析,并按影像参数中位数二分后绘制Kaplan-Meier曲线。
主要发现
- 全部患者中位OS为45个月(95%CI 24-45个月)。
- 单因素分析显示首次再分期PET/CT获得的MTV(MTVpost)是PET/CT参数中对OS最强的预后因素(P<0.0001)。
- 高MTVpost(≥23.44)患者中位OS为16个月(95%CI 12-32个月),低MTVpost(<23.44)患者超过60个月(P=0.0003)。
- 多因素模型显示MTVpost和中枢神经系统病灶的存在是OS的独立预后因素(P分别为0.0004、0.0167)。
- 本队列中1例(1.2%)假性进展,归入高MTVpost组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to investigate the prognostic value of whole-body metabolic tumor volume (MTV) and other metabolic tumor parameters, obtained from baseline and first restaging 18F-FDG PET/CT scans in melanoma patients treated with immune checkpoint inhibitors (ICIs). METHODS: Eighty-five consecutive melanoma patients (M, 57; F, 28) treated with ICIs who underwent PET/CT scans before and approximately 3 months after the start of immunotherapy were retrospectively enrolled. Metabolic tumor parameters including MTV for all melanoma lesions were measured on each scan. A Cox proportional hazards model was used for univariate and multivariate analyses of metabolic parameters combined with known clinical prognostic factors associated with overall survival (OS). Kaplan-Meier curves for patients dichotomized based on median values of imaging parameters were generated. RESULTS: The median OS time in all patients was 45 months (95% CI 24-45 months). Univariate analysis demonstrated that MTV obtained from first restaging PET/CT scans (MTVpost) was the strongest prognostic factor for OS among PET/CT parameters (P < 0.0001). The median OS in patients with high MTVpost (≥ 23.44) was 16 months (95% CI 12-32 months) as compared with more than 60 months in patients with low MTVpost (< 23.44) (P = 0.0003). A multivariate model including PET/CT parameters and known clinical prognostic factors revealed that MTVpost and the presence of central nervous system lesions were independent prognostic factors for OS (P = 0.0004, 0.0167, respectively). One pseudoprogression case (1.2%) was seen in this population and classified into the high MTVpost group. CONCLUSION: Whole-body metabolic tumor volume from PET scan acquired approximately 3 months following initiation of immunotherapy (MTVpost) is a strong prognostic indicator of OS in melanoma patients. Although the possibility of pseudoprogression must be considered whenever evaluating first restaging PET imaging, it only occurred in 1 patient in our cohort.
引用
- Nakamoto R, Zaba LC, Rosenberg J, et al. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 32296882. doi:10.1007/s00259-020-04792-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。